About AesRx
AesRx is a Healthcare company based in Newton (United States) founded in 2009, and was acquired by Baxter in July 2014. Prophylactic treatments for sickle cell disease were developed. AesRx has raised $1.96 million across 4 funding rounds from investors including Baxter and HHS. Its focus areas include Life Sciences, Rare Diseases, Drugs and Hematology. Its legal entity is AesRx, LLC. Its competitors include Editas Medicine, GBT and LogicBio; 3 of its 3 listed competitors have raised funding.
Company details
AesRx was founded in 2009 in Newton, United States, as a clinical-stage biotechnology company. Focus was placed on developing therapies for sickle cell disease, with operations centered on small molecule compounds. The lead candidate, Aes-103 (5-hydroxymethylfurfural), was advanced to phase 2 trials to enhance hemoglobin oxygen affinity and reduce red blood cell sickling, addressing outcomes like vaso-occlusive crises and anemia. Acquisition by Baxter occurred in July 2014.
Funding Insights of AesRx
AesRx has successfully raised a total of $1.96M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $400 thousand completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.96M
- Total Rounds 4
- Last Round Grant — $400,000
- First Round $1.51M
(Jun 2011)
- Investors Count 1
All 4 funding rounds of AesRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $400,000 | Grant | – | – | |
| Dec 2013 | $600,000 | Seed | – | – | – |
| May 2013 | $1.36M | Seed | – | – | – |
| Jun 2011 | $1.51M | Debt – Conventional | – | – | – |
2 investors in total: 2 institutional.
Investors in AesRx
AesRx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Baxter and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Biosciences, medication delivery, and renal products are developed and marketed. | 1931 | baxter.com | Deerfield, United States |
Investor details for AesRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AesRx
4 dated milestones of AesRx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded AesRx is founded.
- Funding First funding round of $1.5M.
- Exit Acquired by Baxter.
- Funding Latest funding round, Grant, of $400K.
Competitors of AesRx
AesRx has 3 listed competitors in our database, 3 of them funded. They include Editas Medicine, GBT and LogicBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. | |
| gbt.com | 2011 | San Francisco, United States | $177.4M | 457 | Small molecules are developed for sickle cell disease treatment. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. |
Detailed competitors of AesRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as AesRx (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AesRx
AesRx was founded in 2009 and raised its 1st funding round 2 years after it was founded.
AesRx is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
AesRx is a funded company, having raised a total of $1.96M across 4 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.51M, raised on Jun 2011.
AesRx was founded in 2009 in Newton, United States, as a clinical-stage biotechnology company. Focus was placed on developing therapies for sickle cell disease, with operations centered on small molecule compounds. The lead candidate, Aes-103 (5-hydroxymethylfurfural), was advanced to phase 2 trials to enhance hemoglobin oxygen affinity and reduce red blood cell sickling, addressing outcomes like vaso-occlusive crises and anemia. Acquisition by Baxter occurred in July 2014.
AesRx's top competitors include GBT, Editas Medicine and LogicBio.
AesRx operates through Aesrx, Llc.
Yes. AesRx was acquired by Baxter in July 2014.